SVS Institute of Dental Sciences, Mahabubnagar
Hyderabad, Andhra Pradesh, 509002, India
NCT Number: NCT02645669
Saccharomyces boulardii is commonly employed as a live non-pathogenic probiotic microbial feed or food supplement. S. boulardii reduces the secretion of key pro inflammatory cytokines and promotes the production of anti-inflammatory cytokines such as IL-10, which is pertinent in the context of pathogenic mechanisms in periodontitis.
Looking for future studies?
Notify Me25 year–50 year
All sexes
Interventional
Phase 2
Hyderabad, Andhra Pradesh, 509002, India
One method of altering the subgingival environment is by using probiotics. Probiotics are live microorganisms, which when administered in adequate amounts, confer a health benefit on the host by passively occupying a niche that may otherwise be colonized by pathogens. This tends to limit a pathogen's ability to bind to tissue surfaces and to produce virulence factors.8 In the past few years, probiotics have been investigated for periodontal health. Studies have shown that certain gut bacteria can exert beneficial effects in the oral cavity by inhibiting pathogenic species. Teughels et al., in a study showed that application of beneficial oral bacteria subgingivally after scaling and root planing led to a more host compatible subgingival microbiota which may also effect the promotion of a beneficial host response.10 Studies have revealed that probiotic Lactobacillus strains (L. reuteri, L salivarius, L. casei, L. acidophilus) were useful in reducing gingival inflammation and the number of black-pigmented rods, including Porphyromonas gingivalis, in the saliva and subgingival plaque. Streptococcus sanguinis & S. uberis were found to inhibit the growth of periodontopathogens & a strong negative between Aggregatibacter actinomycetemcomitans and S. sanguinis. Weissella cibaria isolates in the form of probiotic rinse possess the ability to inhibit biofilm formation, both in vitro and in vivo.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The probiotic is in the form of a lyophilized powder containing approximately 5 billion colony forming units (CFU) of the Saccharomyces boulardii. At the time of administration, the probiotic mixture was mixed with fructooligosaccharide in the ratio of 4:1 to induce growth and activity in S boulardii. This was applied after scaling and root planing.
Only Scaling and Root planing was done.
Time frame: up to 14 days
S boulardii-FOS mixture was stored for 3 weeks at 25ºC for periodic analysis (upto14 days) of microorganism viability on a selective medium. Briefly, the mixture was plated on Sabouraud's agar plates at 30°C and colony forming units (CFU) were enumerated after 24 to 48 h of incubation. Colonies were expressed as total log count per mg of sample (log10 CFU/mg).
Time frame: up to 7 days
Viable cell count was determined by serial dilution method on Emmons' modification of Sabouraud's agar medium and colonies were expressed as total log count per ml of sample (log10 CFU/ml). Only colonies that were opaque, light brown, smooth and 2-3 mm in diameter were counted.
Time frame: up to 6 months
Gingivitis (Modified gingival index; MGI) was measured at baseline and up to 6 months after treatment.
Time frame: up to 6 months
Plaque (Plaque index; PI) was measured at baseline and up to 6 months after treatment.
Time frame: up to 6 months
Probing pocket depth (in mm) was measured at baseline and up to 6 months after treatment.
Time frame: up to 6 months
Clinical Attachment Level (CAL) was measured at baseline and up to 6 months after treatment.
SVS Institute of Dental Sciences
Other
Effect of a Locally Delivered Probiotic as an Adjunct To Scaling And Root Planing In The Management Of Chronic Periodontitis
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06893107
Chronic Disease, Chronic Periodontitis
Fujairah, Emirate of Fujairah, United Arab Emirates
View Trial DetailsNCT04274244
Alveolar Bone Loss, Bone Diseases
Valencia, Spain
View Trial DetailsNCT07671456
Aggressive Periodontitis, Chronic Disease
View Trial DetailsNCT03863249
Alveolar Bone Loss, Bone Diseases
Valencia, Spain
View Trial Details